<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-166465</identifier>
<setSpec>1131-3587</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Review of the principal RE-LY substudy results</dc:title>
<dc:description xml:lang="en">Since the initial publication of the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study results, a total of 10 subanalyses of RE-LY data have been reported. In particular, the efficacy of administering 110 mg or 150 mg of dabigatran every 12 hours for preventing stroke and systemic embolism has been compared with that of warfarin in different clinical contexts. The study results demonstrate that dabigatran is superior to warfarin in terms of anticoagulation control, irrespective of whether patients had previously used warfarin or were taking it for the first time, whether or not they had previously had a stroke, and whether or not they had undergone electrical or pharmacologic cardioversion. Dabigatran was also found to be superior in Japanese patients, in different age groups and in patients with varying levels of stroke risk. In addition, a pharmacokinetic analysis of dabigatran in the RE-LY study population and two cost-benefit analyses have also been published. Together, these study results have achieved an equivalent impact factor of 200 and provide further evidence that dabigatran is superior to warfarin in the prevention of stroke and systemic embolism (AU)</dc:description>
<dc:creator>Romero, Nieves</dc:creator>
<dc:creator>Nevado, Jaime</dc:creator>
<dc:creator>Barón Esquivias, Gonzalo</dc:creator>
<dc:creator>Martínez, Ángel</dc:creator>
<dc:creator>Guisado, Agustín</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Desde la publicación del estudio Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY), se ha publicado un total de 10 subanálisis de sus datos. La eficacia de dabigatrán a dosis de 110 y 150mg cada 12h comparado con warfarina para prevenir ictus y embolias sistémicas se ha analizado en diferentes contextos. Se han publicado los resultados que demuestran la superioridad de dabigatrán frente a warfarina en relación con el control de anticoagulación de los pacientes, si habían usado previamente warfarina o era la primera vez que la usaban, si habían tenido previamente un ictus o no, si se habían sometido a cardioversión eléctrica o farmacológica, si eran población japonesa, en diferentes franjas de edad de los pacientes y diferentes niveles de riesgo de sufrir un ictus. Además, se ha publicado un análisis farmacocinético de dabigatrán en la población incluida en el estudio RE-LY y dos análisis de coste-beneficio. Los resultados de todos estos estudios aportan más de 200 puntos de factor de impacto y respaldan la superioridad de dabigatrán frente a warfarina para prevenir ictus o embolias sistémicas (AU)</dc:description>
<dc:source>Rev. esp. cardiol. Supl. (Ed. impresa);12(supl.B): 31b-36b, 2012. tab</dc:source>
<dc:identifier>ibc-166465</dc:identifier>
<dc:title xml:lang="es">Revisión de los resultados de los principales subestudios del estudio RE-LY</dc:title>
<dc:subject>^d1287^s22057</dc:subject>
<dc:subject>^d14308^s22054</dc:subject>
<dc:subject>^d15261^s22079</dc:subject>
<dc:subject>^d55927^s22079</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d34247^s22054</dc:subject>
<dc:subject>^d34262^s22054</dc:subject>
<dc:subject>^d932^s22079</dc:subject>
<dc:type>article</dc:type>
<dc:date>201200</dc:date>
</metadata>
</record>
</ibecs-document>
